Adéquation et efficacité de l'Adalimumab dans une cohorte suisse multicentrique de patients avec maladie de Crohn by Stelle, M.
UNIVERSITE DE LAUSANNE - FACULTE DE BIOLOGIE ET DE MEDECINE 
Département de Médecine 
Service de Gastro-entérologie 
Adéquation et efficacité de l'Adalimumab dans une cohorte suisse 
multicentrique de patients avec maladie de Crohn 
THESE 
préparée sous la direction du Professeur ·associé Pierre. Michetti 
et présentée à la Faculté de biologie et de médecine de 
l'Université de Lausanne pour l'obtention du grade de 
DOCTEUR EN MEDECINE 
Par 
Marc STELLE 
'/ 
., 
~, r; ,)ei, 
tJ ') .. () ~J 
) lt Médecin diplômé de la Confédération Suisse 
Originaire de Genève (GE) 
1 
Lausanne 
2010 
1 
l3i1Jlioti·1èque U11iw1rnitaire · 
de 110 / UIVl 
CH 
Ecole Doctorale 
Doctorat en médecine 
Imprimatur 
. . 
Vu le rapport présenté par le jury d1examen, contpose de 
Directeur de thèse 
·Co-Directeur de thèse 
Expert 
Directrice d~ l'Ecole 
· doctorale · 
Monsieur le Professeur associé Pierre Michetti 
·\ 
Monsieur le Professeur associé François Spertini 
Madame le Professeur Stephanie Clarke 
la Commission MD de l'Ecole doctorale autorise l 1impression de la thèse de 
Monsieur Marc Stelle 
intitulée 
Adéquation et efficacitè de l'Adalimumab dans une cohorte 
suisse multicentrique de patients avec maladie de Crohn 
Lausanne, le 19 octobre 2010 
pour Le Doyen· 
de la Faculté de Biologie et de Médecine 
_C1~--ep 
Madame le Professeur Stephanie Clarke 
Directrice de l'Ecole doctorale 
Adéquation et effi~acité. de l'adalimumab dans une cohorte suisse 
111ulticentrique de patients avec maladie de Crohn 
·Résumé 
. De nombreux es.sais cliniques randomisés ont démontré l'efficacité de l'adalimumab chez l'es 
patients atteints de maladie de Crohn mo.déréè à sévère. Néanmoins, l'expérience sur le 
long terme est très limitée dans la pratique médicale quotidienne. 
' . 
But : Vérifier l'efficacité, la sureté et l'adéquation de l'adalimumab dans une cohorte suisse 
multicentrique de patients atteints de maladie de Crohn. 
Méthode : Nous avons étudié rétrospectivement les dossiers de patients atteints de la 
maiadie de Crohn traites par adal~niumab sur une période de 3 ans. L'activité de la maladie a 
été mesurée par l'index de Harvey-Bradshaw (HBI). Une rémission correspondant à un 
score :::;;4 points et une réponse clinique à uhe diminwtion du HBI de >3 points par rapport au 
score· pré-traitement. Pour évaluer l'adéquation de l'adalimumab, nous avons utilisé les 
critères développés par l'European Panel on the Appropriateness of Crohn's disease 
·• Therapy (EPAC.T Il). 
R.ésultats : Les dossiers de. 55 patients ont été anàly.sés. Le taux de rémis.sion et de 
réponse observ~s après 4 à 6 semainE?s était respectivement de 52.7% et 83.6%. La 
rémission a été maintenue à 12, 24 et 52 semaines chez respectivement 89.6%, 72.4% et 
44.7% des patients. La rémission et la réponse clinique au traitement n'étaient pas correlés 
au status tabagique du patient, à la localisation ou la durée de la maladie, à la dose totale 
reçue le premier mois ou à un précédent traitement. par infliximab. Le taux de rémission 
après 4 à 6 semaines de tra·itement était significativement plus élevé chez les patients ayant 
développés une intolérance à l'infliximab par rapport .à èeux devenus réfractaires à ce 
- \ . . 
traitement. L'adalimumab a été globalement bien toléré. 59 % des indications à l'adalimumab 
ont été adéquates. 
Conclusion : L'adalimumab peut être considéré comme un traitement efficace et approprié 
à long terme chez les patients avec une maladie de Crohn modérée à sévère. 
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Abstract 
. . . 
Background: Controlled clinicaltrials have demonstrated the efficacy and safety of adalimumab in 
patients with moderate-to-severe Crohn's disease (CD), but there is, however, only limited long-term 
experience with adalimumab in daily practice. 
Aim: To assess the long-term effectiveness, safety and appropriateness of adalimumab in a 
multicenter cohort of practice-based patients with moderate-to-severe CD. 
Methods: We retrospectively reviewed the chartsof CD patients whù received adalimumab over a 3-
year period. Disease se.verity was scored using the Harvey-Bradshaw Index (HBI). Remission was 
defined as HBI of s 4 and response as a reduction in the HBI of >3 points at evaluatioti compared to 
j •• 
the baseline. To assess appropriateness of adalimumab, we .used the criteria developed by the 
European Panel on the Appropriateness of Crohn's disease Therapy(EPACT Il). Univar,iate logistic 
regression analysis was used to identify the predictive variables associated with response~ 
Results: The charts of SS patients wei:e reviewed; remission and response rates observed at week 4-6 
were S2.7% and 83.6% respectively. Remission was maintained at week 12, 24 and S2 in 89.6%, 
72.4% and 44.7% of patients respectively. Remission and response rates were not influenced by 
smoking status, disease location or duration, the first-month total dose, or previous infliximab 
therapy. Re mission rate .at week 4-6 was significantly higher in patients intolerant of infliximab as. 
compared to ~hose wh9 lost response tq this drug. Adalimumab was well tolerated overall. S9% of 
adalimumab indications were rated appropriate. 
Conclusion : Adalimumab can be considered a suitable and appropriate option in patients with 
moderate"to-severe CD, demonstrating sustained long-term effectiveness. 
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Introduction 
Tumor necrosis factor a (TNF-a) has emerged as a central cytokine iQ the pathogenesis of 
Crohn's disease (CD), as is confirmed by the central raie that TNF-a antagonists have now acquired in 
the treatment of patients with moderate-to-severe or refractory CD. lnfliximab (IFX), the first 
chima~ric monoclonal TNF-a antibody, is an effective treatment for induction and maintenance of 
remission in patients with moderate-to-severe Crohn's disease, including those with draining fistulas 
(1-4]. However, a proportion of patients develop antibodies t.o infliximab (ATI), in particular with . 
. . . 
episodic therapy or in the absence of concomitant immunosuppressant medication. The presence of 
ATI leads to infusion reactions, loss of response and.delayed hypersensitivity reactions (5-7]. 
Adalimumab is a subcutaneously-administered recombinant, fully human, immunoglobulin 
Gl monoclonal antibody that l:linds with high affinity and specificity to human TNF. Four pivotai, 
randomised, dolible-blind trials (CLASSIC-1, CLASSIC-11, CHARM and GAIN) in >1400 patients 
demonstrated clinical efficacy and safety of adalimumab in patients with moderate-to-severe Crohn's 
disease (8-11]. Adalimllmab was significantly more effective than placebo for induction of remission 
in patients na ive to anti-TNF therapy (CLASSIC-1 trial, 36% vs 12% at week 4with 160/80 mg regi.men, 
p=0.004) or in those who had either lost responsiveness or developed intolerance of infliximab (GAIN 
trial, 21% vs 7 .2% at week 4, p<0.001). Thé CHARM trial showed that, among patients w~o 
responded to open-label adalimumab induction, maintenance therapy with adalimumab 40mg 
weeldy or every other week for up to 1 year was associated with significantly greater remission rates 
than placebo at weeks 26 (47%, 40% vs 17%, p<0.001) and 56 ( 41%, 36% and 12%, p<0.001). ln 
an.other maintenance trial {CLASSIC-11), patients who wére in remission after a short course of . 
adalimumab and whà were randomised to receive upto 1 year of treatment with adaJimum.ab 40rng 
weekly (ew) or every other week (eow), were significantly more likely to remain .in r~rniss.ion than 
those who received placebo ( 83%, 79% vs 44%, p<0.05). Loss of efficacy can also be observed with 
. . . 
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adalimumab and an increased dose can be used to r.estore clinical response or remission. The.raie of 
antibodies to adalimumab in the loss of response is to date poorly characterized. 
Adalimumab is generally well tolerated. ln clinical trials, the rate of serio.us adverse events 
was low in patients treated with adalimumab and was similar to those treatèd with placebo [8-11]. 
Patients with Crohn's disease seen in daily practice may differ from the selected patients 
includèd in randomized trials [12-15]. ln a multicenter open-label single-arm study (CARE), 
adalimumab therapy showed substantial efficacy at week 4 (43% remission rate), which was 
sustained through week 20 (52% remission rate),.including in patients who had never responded to 
IFX[16]. Neither concomitant steroids nor immunosuppressants notably affected the results [17]. ln 
. this study, we analyzed our experience with adalimumab in current clinical practice over the past 
three years. 
For niany of the clinical situations in Crohn's disease, there is no high-grade evidence, based 
on randomized controlled trials, concerning the right çhoice of treatment. ln this context, 
appropriateness criteria derived from a validated and well-accepted panel method have the potential 
to asslst the clinician in èlecision-making and to frnprove quality of care. 
ln 2004, the Europ.ean Panel on the Appropriateness of Crohn's Disease Therapy (EPACT) 
convened in Lausanne and brought together 15 experts (10 gastroenterologists, 2 internists/general 
practionners and 3·surgèons) from 12 European countries (Austria, Croatia, De.nmark, France, 
Germany, lreland, Israel, ltaly, Spain, Sweden, The Netherlands, United l<ingdom) to develop detailed 
and specific criteria for the appropriateness of care, using the RAND/UCLA appropriateness method 
[18]. ln 2007, the second European Panel onthe Appropriateness of Crohn's Disease Therapy (EPACT 
li) aimed to update and redefine appropriateness criteria for Crohn's disease ta king into account 
recerit advances in medicine and published lite rature available. [19-23]. The aim of the 
6 
appropriateness criter.ias were to serve as the basis for guidelines concerning therapy in order to 
assist practitioners an.ci patients in choosing èorrect treatment. 
Although the criteria are designed to be used prospectively, we decided in this study to 
evaluate the appropriatenès.s of àdalimumab retrospectively and to see if there was a relationship~ 
'. . . 
between appropriateness and clinical response of treatment.This approach hàs been validated in a 
prior study by our group using the same c'riteria in CD patients, not.restricted tq anti-TNF users [24). 
Patients and Methods 
We performed a retrospective chart review of patients with CD who. had been treated with 
adalimumab at the .University Hospitals of Lausannè, Geneva, Zurich and Olten between April. 2005 
and April .2008, and fifty-five patients who had received adalimumab were identified. The diagnosis 
of Crohn's disease was confirmed in ail cases by a review of patients' medical records including 
clinical notes, endoscopi,c, radiographie or histological documents. 
The information collected included patient demographics, disease location, disea.se 
phenotype, disease duration, prior surgical procedures, smoking status, previous anti-TNF and 
immunosuppressant use, concomitant medication, disease activity at baseline and during treatment. 
Qisease severity for ruminai Crohn's disease was scored using the Harvey-B:adshaw index (HBI) [25). 
Fbr patients with previou:S surgical resections, other causes of diarrhoea, such as bile sait 
malabsorbtion, small bowel bacterial overgrowth, or deficient water absorption secondary to 
proctocolectomy, were eliminated before consideringthem for adalimumab therapy: 
First clinical evaluation was performed at week 4-6. Subsequent assessments of efficacy of 
treatment were performed at week 12, 24 and 52. The clinical evolution of luminal CD was clçissified 
irito three categories: remission, response and non-response. Remission was defined as an HBI of :::_4 
7 
' / 
and response as a reduction in the HBI 'of 2_3 points atthe évaluatiçrn week èompared to the baseline 
index[26]. The non-respo.nse category included ail the remaining patients. 
Data on clinical safety were collected at èvery medical visit and the patients were a.lso 
instructed to contact the physician's office ifany illness .or adverse reaction occurred. Patients were 
considered intolerant to IFX if they were unable to continue the treatment due to reactions judged ·· 
by the clinician to be li.nked to the perfusion. Lass of responsiveness to IFX was accepted if patients 
. did not achieve remission with an increased IFX regimen after loss of efficacy at a standard dose. 
To evaluate apprqpriateness, CD category was established for each patients using EPACT 
criteria available on the EPACT website (www.epact.ch). lt must be emphasized that a patient cou Id . 
be in more than one càtegory. For example, a patient cou Id have an active lun:inal disease and extra-
. intestinal manifestations of his CD. EPACT criteria are based on the Crohn's Disease Activity Index 
(CDAI) known to correlate closely with HBI [25]. ln an article published in 1980, William R. Best 
evaluated th.e two scores and found that a 1 point increase in HBI corresponds to a 27-point increase 
in the CDAI [27]. A remission (HBI of <4 points) corresponded to a mean CDAI from 26 ± 26 to 134 ± 
. . ' ' ' 
39 and a clinical response (reductiori in the HBI of >3 points) to a CDAI reduction of 8:1, points. 
We used univariate logistic regression analysis to see if the predictive variables tésted (table 
2,3) were implicated ·in the response rate. The variables which had a p value <0.3 were tested, then 
together in a multivariate analysis in order to contrai for the confounding effect of each. Ap value of 
. . ' . ' 
<0.05 was considered to be statistically significant. Data are expressed according to a per-protocol 
analysis. Ali quantitative variables are expressed as the mean.± standard error. 
. . 
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Results 
This cohort comprised 55 patients (21 men and 34 women), mean age 37.S years (±11.4 
years) treated with adalimumab between April 2005 and April 2008. The demographic data and 
baseline clinical characteristics are summarized in Table 1. The mean du ration of Crohn's disea~e was 
12.7 years (range 1-41 years). Description of disease location of luminal CD followed the usual 
distribution. One patient had ileal, colonie. and oesophageal disease. The mean HBI before trèatment 
. . 
was 10.9 points (f5 point~): Twenty-nine patients were smo.kers. Adalimumab was administered to 
patients intolerant to IFX, to those who had lost response· to IFX, or to those who were · 
corticodependent. Seven patients were treated thus for other réasons,· two of whom had severe 
spondylarthropathy'; The indication for adalimuniab therapy in the 4 patients who had an HBl<4 
points at inclusion was intolerance to IFX (1 patient), lupus-like syndrome with IFX (1 patient) and 
corticodependence (2 patients). These patients were considered to be in remission if their HBI 
.remained belovJ 4, or were deemed non-responders if the.ir · HBI value rose du ring the follow-up 
period. Of those who had already received IFX, 25 ·patients had episodic infusions and 18 patients 
had regular treatment. Ali patients received subcutaneous injections of adali.mumab at week O and 2 
at a dose of 160mg/80 mg (31 patients) or 80mg/40mg (24 patients) and then 40mg every other 
week. The results of detailed subgroup analysis are summarized in Table 2 and Table 3. 
Adalimumab induces and inaintaitjs clinical remission ànd response in CD patients. At week 
· 4-6, in per protocol anàlysis, remission had been induced in 29 patients (52.7%) and'response was 
noted in 46 patients (83.6%). An adalimuma.b-induced remission was maintained in 26 patients 
. (89.6?0) at week 12 and in 21 patients (72.4%) at weèk 24, respectively. The evolution over time of 
remission and response rates in per-protocol analysis is shown in Figure 1. However in a intention-ta~ 
\ . . 
treat analysis remission was hoticed in 47.3% patients et'week 24 and in. 31% patients at week 52, 
respectivelly. Response rates at the same time-points were 54.5% and 34.5% respectively.Thirteen 
patients (23.6%) requfred an increase in the adalimumab dose: nine patients to 40 mg every week, 
9 
two patients to every 10 days, one patient to 80 mg every week and another to 80 mg every 2 weeks, 
. because of iricomplete response or loss of response. Of these 13 patients, 6 {46.1%) achieved 
remission.and another 2 patients responded. ln one patient, the dose was redu.ceci to 40 mg every 4 
weeks bècausè of fatigue. The response rate was not significantly higher in thé group of patients with 
j:Jreviolis abdominal surgery (Table 2). 
Effect of dmoldng on Adalimumab efficacy at week 4-6. The remission and response rates 
. . . 
were higher among the non-shloker, but without any statistically significant difference. 
Effect of disease duratio~ or location on adalimumab efficacy at week 4-6. Beca use of the 
long mean disease duratiÔn in our cohort, we èh.ose to separate the patients in three almost equal 
groups: CD known for <7 years, for 7-15 years and for >15 years. The remission and response rates 
were almost similar within the se 3 groups. The location of the intestinal segment(s) involved was not 
found to play a signlficant role in, patients' clinical response to the adalimumab therapy. 
Effect of the first-month total dose on adalimumab efficacy at week 4-6. Remlssioti and 
response rates were not different between the groups who received adalimumab 240mg or 120mg 
du ring the first month of treatment. The total first-tnonth adalimumab dose was divided by the 
patient's weight and pàtients were then grouped into 3 dose-adjusted groups ac_cording tothe total 
(:!ose per kg over the first month: <2.5 mg/kg, 2.5-3.5 mg/kg and >3.5 mg/kg. We did not find s;rny 
. statistically significant difference between the~e three groups with regard to the response rate. 
Impact of prior infliximab treatment on adalimumab effica.cy at week 4-6. The responsè 
rate was not influenced by the absence of previous IFX treatment or by its regular as opposed to 
episodic use. ln contrast; the remission rate at week 4-6 was significantly higher among patients 
intolerant to infliximab, compared to those wh.o had lost response to this medication {78.9% vs 
42.1%, p=0.02). 
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Safety of adalimumab treatment. Ove rail, subcutaneous injections of adalimumab were well 
tolerated (Table 4). Thirty of the 55 patients reported no adverse event The most common side-
effett was pain at the injection site (10.9%), followed by asthenla (9%) and infections (7.2%). One 
patient stopped the treatment because of intolerable fatigùe and another because of gynaecological 
side-effects. One case of lupus-like syndrome was noted. ln our cohort, no fatal complication, 
malignancy, neurologie or cardio~~scular complication was noted du ring the whole of the 
observation period. 
Appropriateness of Treatment. Crohn's disease EPACT Il category was established for each of 
the 55 patients. We analysed the appropriateness of adalimumab for the different categories of CD 
' ' 
(Table 5). lt showèd that adalimumab was appropriately used for 59% of clinical situations, uncertain 
for 34.5%, while 6.5% were inappropriate: Ali fistulizing cases were rated uncertain, mostly due to a 
lad< of randomized contr~lled studies evaluating ad.alimumab in penetrating CD. Fibro-stenotic cases 
were ail inappropriately treated. 
Appropriateness and clinical response at week 4-6. The response rate was higher in cases 
where adalimumab was either appropriate or uncertain compared :o inappropriate cases, without 
any statistically significant difference (Table 6). 
Discussion 
The purpose of our retrospective cohort study was, to evaluate the effecti\(eness of.· 
adalimumàb in daily clinical practice in our,Crohn1s patients over a period of 3 years. Adalimumab 
treatment was effective in induction and maintenance of remission in patients with moderate-to-
, . 
, severe Crohn's disease. The results in our cohort appear better than the remission and response 
rates noticed in the CLASSIC 1 triçil (36% and 59% respectively at week 4) (8) and the GAIN trial (21% 
and 52% respectively at week 4) [11). The fact that in our cohort the first evaluation occurred later 
than that in those trials, i.e. that our patients had a supplementary third injection, may have 
11 
contributed to the improved results. ln per-protocol analysis, 44.7% patients were in remis.sion and 
50% still in response at week 52. These long term results for remission are similar to those at week 
56 in the C~ASSIC Il trial [9]. The limited size of our cohort, the lack of placebo contrais and the 
absence of restric~ed inclusion criteria may have contributed to the differences noticed in our 
patients. ln addition; we used the HBI rather than the Crbhn's Disease Activity Index to evaluate 
pati~nts, which could also in part expia in the difference from the randomized trial. The remissio'n and 
respons.e rates in our cohort are also comparable to those of the CARE study [16,17], although in this 
· multicenter cohort ail patients received a 160/80mg induction regimen.· 
The proportion of our patients who needed a dose increase, and ~he benefit obtained with 
thi~ strategy, was similar to that. reported in the CHARM trial [28]. ln ~ur cohort, the mean time fo 
dose increase was relatively long: 7 months (range 1-24 months). Our results thus confirm that in 
clinical pradice this strategy should be explored before cons.idering another treatment in patients 
who !ose response or fail to achieve compJete remission with a standard adalimumab regimen. ln a 
· small study, a highèr percentage of patients were previously repbrted to require adalimumab dose-
increase (nearly 60% at 6 months), using a suboptimal induction regimen of 80mg/40mg [12]. ln 
ano'ther two cohorts, only 13.2% and 29% of patients respectively required dose-increase [14,15]. 
ln a per-protocol analysis, we observed that, over 52 weeks, adalimumab treatment was 
stopped in half ofthe patients. This dropout rate was progressive during the observation period. The 
. ' 
reasons for discontinuation were either no response, loss of response despite dose-increase (14/19 
patients) or adverse reaction (5/19 patients). 
Smoking status had no effect either on the rate of clinical remission o'r on response rate in 
patients treated with adalimumab. This observation is consistent with the results of the sub-analysis 
in the CLASSIC 1 trial, where the efficacy of adalimuma,b treatment at week 4 was not affected by 
. 12 
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smoking status [29]. HinoJosa et al also reported no difference in the 4-week response rate of àctive 
smokers with luminal CD. as compared to former smokers [13]. 
The efficacy of adalimumab therapy in our cohort was not influenced by disease du ration.' ln 
the CHARM trial, Colom bel et al showed a significantly better remission rate at w~ek 26. and 56 with 
adalimumab in patients with CD du ration of <2 years or ).5 yèars (10). We were .unable to sep_arate . 
. our patients into the sa me three groups (disease d.uratioh <2 years; 2~5 years and >5 years) because 
our patients had a longstanding diagnosis of Crohn's disease. Our results suggest that beyond 7 years 
disease duration has no greater impact on response .. 
We failed to show a correlation between the total firstcmonth dose adapted to body-weight 
or the response or remission rate to adalimumab therapy. These results suggest that the dose du ring 
the first month as currently administered should suffice-in the majority of patients. However, the 
small size ·of the cohort and the retrospective nature of the analysis do not exclude the possibility . 
that a dose-weight relationship might exist in a larger group of patients .. lndee"d, as the affinities and 
molecul.ar weight of IFX and _adalimumab are comparable, one cou Id have expected that such a 
relationship might exist. Other characteristics of adalimuniab.mayexplain this difference as 
compared to IFX, su ch as the human nature of the antibody cir differences in the binding sites .of the 
antibodies/ 
The majority of our patients had been treated with IFX before receiving adalimumab, The 
· remission and response rates at week 4-6 were not statistically different in pa.tients na ive fo IFX 
compared to those who had already been treated with IFX. Similarly, no difference was found in the 
response to adalim1-1mab between patients whose previous IFX therapy was interrupted because of 
loss of response or because of intolerance. This last observation was also reported by Hinojosa et al 
[13]. ln contrast, however, the remission rate at week 4-6 was significantly higher in the subgroup of 
patients intolerant to IFX. This suggests that patients who did not lose their response to IFX may 
benefit more from a'nother anti-TNF agent. Patients who.have lost response inay represent a group 
of patients that may better benefit from a change in the treatment target, different from TNF. 
Ove ra li, adalimumab was well tolerated in our cohort. The rate .of side-effects was similar to 
that already reported in randomizedtrials, in which patients underwent more strlngent selection and 
monitoring [8-10]. Pain at injection site, asthenia and infections were the most common adverse 
events. Despîte these reassuring resufts, the safety issues surrounding anti-TNF the ra pies continue to 
be of great significance and clinicians need to remain vigilant. JF Colom bel recently assessed global 
adalimumab safety in a collective of 2228 patients exposed to adalimumab in pivotai randomized 
·:trials, open~label extensions and phase lllb studies, CHOICE and CARE. îhe rates of opportunistic 
infections and of ma lignant neoplasms were found to be <2% of patients [30]. Such rates justify 
careful monitoring of ail patients; even when stable in remission. 
Our study has several limitations. Firstly, the data pr~sented are based on a retrospective 
review and not on a uniform analysis with precise time-points. Secondly, even if this js the largest 
. . . ' . 
• ' • • • 1 ' 
cohort of open-label clinical experience in patients with Crohn1s disease to date, the number of 
patients analyzed at 24 and 52 weeks is still low. Thirdly, our patients had a long standing c;ronh's 
disease history prior to adalimumab.therapy. lt remains to be studied if adalimumab used in a top-
down scheme might improve the results reported here. Although non-significant, the odds ratib 
' ' 
' ' 
·values cannot be ta ken as proof that none 9f the variable mentiOned in Table 2 may have an effett. 
The large confidence intervals indican~ that the calcula~ed odds ratio remains imprecise. 
Concerning appropriateness of adàlimumab, we failedto demonstrate a link between 
appropriateness and response to treatment at week 4-6. If we consider uncertain tre~tment as . 
appropriate, we observe that 94.5% of adalimumab indications were appropriate in our cohort. This 
high appropriateness index can be explained bysever~I factors. Firstly, the use of adalimumab at thi~ 
early stage after introduction was mostly restricted to tèrtiary centers with e.xtensive experience of 
14 
Crohn's therapy.' Secondly, the patients were ail at the end of the therapeutic possibilities, which 
made the choice of adalimumab appropriate in this setting in most cases. Thirdly, the number of 
inappropriate cases limited the value of the statistical analysis. More cases would be required to 
· detect a difference if there would be one. ln any case, t.his high appropriateness index is reinsuring 
regarding a proper resource consumption of this costly therapy in our .country. 
ln conclusion, our data suggest that adalimumab is as effective in inducing and maintaining 
remission in patients with moderate-to-severe or refractory Crohn's disease seen in daily practice as 
reported during randomized trials. Ourresults further suggest t.hat patients with intolerance to IFX 
,,. . 
represent a group particularly well-suited to further.adalimumab therapy. Adalimumab was 
appropriate for.a high majority of our patients. The safety of adalimumab is also confirmed in daily 
practice. However, results from larger cohorts should be awaited beforefeaching firm conclusions. 
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Table 1: Demographic and Baseline Clinical Characteristics 
Patient characteristics · 
Gender 
Male 
Fe male 
Mean age (years) ± SD 
Disease duration (years) 
Mean± SD 
Range 
Smokers 
Yes 
No 
Disease location {Vienna Classification) 
L1: lleal, 
L2: Colonie 
L3: lleocolo.nic 
L4-.: Upper (esophageal) 
Disease behavior (Vienna Classification) -
patients may appear more than once 
Bl: non-strictüring non-penetrating 
B2: stricturing 
B3: penetrating 
Surgery for Crohn's disease 
lleal resection 
. lleocol.onic resection 
N=55 (%) 
21 (38.2) 
34 (61.8) 
37.5 
12.67±11A 
1-41 
29 (52.7) 
' 26 (47.3) 
9 (16.3) 
11 (20) 
35 (63.6) 
1 (1.8) 
35 (63.6) 
7(12.7) 
23 (41.8) 
5 (9) 
12 (21.8) 
20· 
Colonie resection . 
Proctocolectomy 
None 
Previous lnfliximab (IFX) therapy 
Side-effects 
Lass of response 
No/insufficient response 
Never given 
Type of infliximab therapy 
Regular 
Episodic 
Concomitant treatnient 
Budesonide. 
Prednisone 
Azathioprine 
Methotrexate 
Indication of Adalimumab 
lntolerance.to IFX 
Lass of response to IFX 
Corticàdependance 
Other reason a 
Adalimumab induction regimen 
160mg/80mg 
80mg/40mg · 
7 (12.7) 
4 (7.3) 
23 (41.8) 
n=43 
23 /43 (53.4)' 
19 /43 (41.1) 
1/43 (2.3) 
12/55 (21.9) 
18/43 (41.9) 
25/43 (51.8) 
4 (7.3)' 
25. (45.4) 
5 (9) 
3 (5.4) 
19 (34.5) 
19 (34.5) 
10 (18.1) 
7 (12.7) 
31 (56.4) 
24" (43.6) 
a refractory to Certolizumab (3), to Azathioprine(1},extra"intestinal manifestations (2), no response to IFX (1) 
21 
Table 2: Response by subgrotips at 4-6 weeks 
Variable Category Response Non- Univariate regression Multivariate regression 
W4-6; response 
OR (95%CI} p . OR (95%CI). p 
n (%) W4-6, 
n (%) 
Age (years) 38,3 33.4. 1:04 (0.97- 0.249 1.04 (0.97- 0.268 
1.12) 1.12) 
Gender Female 29 (85.3) 5 (14.7) 1 
Male 17 (80.9) 4 {20.1} 0.73 (0.17- 0.673 
1 
3.10) 
Smoking Non- 23. (88.5) 3 {11.4} 1 
status 
' 
smoker 
Smoker 23 {79.3} 6 (20.7}. 0.50 (0,11-. 0:366 
2.24) 
Dise a se <7 15 (83} 3 (17) 1 
du ration 
7-15· 16 (84) 3 (17) 1.00 (0.17-. 1 
(years) 
5.72} 
> 15 15 (83) 3 (17} 0.94 (0.16- 0.942 
5.39) 
.. 
Disease lleitis (Ll) · 8 (80} 2 (20) 1 
22 
. /. 
location Colitis (L2) 10 (91) 1 (9) • 2.22 (0.17- 0.542 
1 
8.86) 
' 
lleocolitis 28 (82:3) 6 (17.3) 1.04 (0.19- 0.968 
(L3) 
6.07) 
" 
Previous No 18 (78.3) 5 (21.7) 1 
resectiôn ,, 
Yes 28 (8T5) 4 (12.s) . 1.94 (0.46- 0.366 
(any 
8.22) 
segment) 
Previous IFX Never 9 (75) 3 (25) 1 
therapy 
Episodic 21 (84) 4 (16) 1.57 (0.29- 0.595 
8.41) ' ,, 
Regular 16 (88.9) 2 (i0.1) 2.40 (0.34- 0.380 
6.97) 
Indication loss of 17 (89.4) 2 (10.6) 1 1 
for response to 
adalimumab IFX 
' 
lntolerance 17 (89.4) 2 (10.6) 0.94 (0.12- 0.957 1 
' to IFX 7.48) 
Other* 12 (70.5) 5 (20.5) 0.27 (0.04~ 0.149 0.33 (0.07- 0.182 
1.61) i'.68) 
23 
First-month 120 19 (79.2)· 5 (21) 1 
.. 
total dose 
(80+40) 
1 
(mg) 
240 27 (87.1) 4 (13) 1.00 (0.99- . 0.434 . 
. {160+80) 1.02) 
First-month < 2.5 17 (80.9) 4 (19.1) 1 1 
total 
2.5 -3.5 13 (76.4) 4 (23.6) 0.72 (0.15- 0.682 1 
dose/weight 
3.43) 
(mg/kg) 
> 3.5 16 (94.1) 1 (5.9) 3.56 (0.36- 0.278 3.87 (0.38- 0.251 
. ' 
5.20) 39.03) 
. . . 
Cort1codependence (n=lO) and other (n = 7) merged because of small numbers. 
24 
Table 3: Rémission by subgroups at 4-6 weeks 
Variable Category Remission W4-61 Non-remissièn p-value 
n(%) W4-6, n{%) 
Smoker status Smoker 12 (41.4} 17 (58.6} 0.075 
Non-smoker. 17 (65.4} 9 (34.6} 
Previous IFX Regular 10 (55.5) 8 (44.5} 0.719 
therapy 
Episodic ~2 (48} 13 (52} 
Never 7 (58.3) 5 (41.7} 
Indication for · Loss of response 8 (42.1} 11 (57.9) 0.012 
adalimumab to IFX 
lntoleran'ce to IFX 15 {78.9) 4 (21.1} 
25 
Table 4: Adverse events ~bserved over the 3-year period 
Type of adverse event N 
None 35 
Perianal abscesses 2 
Asthen,ia 5 
Pàin at injection site 6 
Pruritis at injection site 2 
Rash 1 
Headache 3 
Nausea 2 
Diarrhoea 1 
Dizziness 2 
Phlebitis 1 
Gynecological side-effect 1 \ 
Labial herpes 1 
Lupus-like syndrome 1 
26 
Table 5: Appropriateness of adalimumab by EPACT Il c'riteria 
EPACT Il category Number Appropriate Uncertain lnappropriate 
Mild to Low 21 .16 2 3 
Moderate Active 
\ 
Luminal 
High Moderate tp 21 17 4 -
Severe Active 
.. 
Lu minai 
Steroid- 24 16 8 -
Dependeht .. 
Steroid~ 20 20 - -
Refractory 
Fistulizing 25 - 25 " '-
Fibro-s~enotic .4 - - 4 
Maintenance of 4 1 2 1 
Medically-
induced 
Remission 
. Upper 1 - 1 -
Gastroduodenal · 
Extra intestinal 5 4 1 -
Manifestations 
Total 125 (100%) 74 (59%) 43 (34.5%) 8 (6.5%) 
Table 6: Appropriateness and clinical respànse 
n=125 Response No response Total P value 
n (%) n {%) 
Appropriate and Uncertain 103 (88) 14 (12) 117 0.21 
lnappropriate 6 (75) . 2 (25) 8 
27 
Figure 1 : Response and remission rate over time in peroprotocol analysis. 
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Resu/ts:.The charts of S5 patients were revlewed; remiss'fon 
·and response rates observèd at weeks 4-6 were 52,7 and 
83.6%, respectively, Remission was maintained at weeks 12, 
24 and 52 in 89.6, 72.4 and 44.7% of patients, respectively, 
Remission and response rates were not influenced by smok-
Abstract ing status, disease location or du ration, the first month total 
Background: Controlled clinical trials have demolistrated dose, or previôus infiiximab therapy. The remission rate at 
·the efficacy and safety of adalimumab in patients with rnod- weeks 4-6 was significantly higher in patients intolerarit of 
· erate-to-severe Crohn'.s disease (CD), but there is, however, " infliximab as tompared to those who lost response tci this 
only limited long-term experience with adalimumab in daily drug, Adalimumab was .well tolerated overall. Conclusion: 
practice. Aim: To assess the long-term effectiveness and Adalimumab can be considered a suitable option in pàtients 
safety of adalimumab in a multicenter cohort of practice- with moderate-to-severe.CO, demonstrating sustained long-
based patients with moderate-to-severe CD. Methods: We term effectiveness. Copyright© 2010 s. Karger AG, Ba sel 
retrospectively reviewed the charts of CD patients wh6 re-
ceived adalimumab over a 3-year period. Disease severity 
was scored using the Harvey-Bradshawïndex (HBI). Remis-
. sion was defilwd as an HBI of :::;4 and response as a r.educ-
tion in the HBI of >3 points at evaluation compared to 'the 
baseliné. Univariate iogistic regression analysis was used to 
identify the predictive variables assoclated with response. 
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Introduction · 
Tumor necrosis factor œ (TNF-Œ) has emerged as a 
central cytokine in the p~thogenesis of Crohiù disease 
(CD), as is confirined by the central role that TNF-Œ anc 
tagonists now play in the treatment of patients with mod-
erate-to-severe or refractory CD. Infliximab (IFX), the 
first chimeric monoclonal TNF-Œ antibody, is an effec-
tive treatment for induction and maintenance of remis-
sion in patients whh moderate~to-severe CD, including 
p1ose with draining fistulas (1-4]. However, a proportion 
of patie'nts develop a~üibodies to IFX, in partici.llar with 
episodic therapy or in the absence of concomitant immu-
nosuppressant medication .. The presence of antibodies to 
IFX leads to infusion reactions, loss of response and.de-
· 1ayed hypersensitivity reactions (5-7]. 
Adalimumab is a subcutaneously administered re-
combinant, fully lmman, immunoglobulin Gl monoclo-
nal àntibody that binds with high affinity and specificity 
to human TNF. Four pivotal, randomized, double-blind 
trials (CLASSIC-I, CLASSIC-II, CHARM and GAIN) in 
:>l,400' patients demonstrated the clinical efficacy and 
safety of adalimumab in patients with moderate-to-se-
vere CD (8-11]. Adalimumab was significantly more ef-
fective th an placebo for induction of remis si on in patients 
naive to anti-TNF therapy (CLASsrc~r trial, 36 vs. 12% at 
week 4 with 160/80 mg regimen, p = 0.004) or in those 
who had either lost responsiveness or developed intoler-
ance to IFX (GAIN trial, 21 vs. 7 .. 2% at week 4, p < 0.001). 
The CHARM trial showed that, among patients who re- · 
sponded to open-label adalfommab inductioi:i., mainte-
nance' therapy with adalimumab 40 mg weekly or.eveq 
other week fo1: up to 1 year was associated with. signifi- · 
cantly greatel' remission rates than placebo at weeks 26 
(47, 40 vs. 17%, p < 0.001) and 56 (41, 36 and 12%, p <. 
0.001). In anothér maintenance trial (CLASSIC-II), pa-
tients who were in remission after a short course of adali~ · 
muinab and who were randomized to réceive up to lyear 
of .treatment with adalimumàb 40 n1g weekly or every 
other week, were significaritly more likèly to rèmain in 
remission than those who received placebo (83, 79 vs. 
· 44%, p < 0.05). Loss of efficacy can also be observed with 
adalinmmab and an increased dose can be .used to restore 
clinical response or re.mission. The role of antibodies to 
adalimumab in the loss ofresponse is 'poorly character-
ized to date. · 
Adalimumab is generallywell tolerated. In clinicaltri-
als, the rate of serious adverse events was low in patients 
treated with adali~numab and was similar to those treat-
ed with placebo [8..:.11]. 
Adalimumab in Crohn's Disease 
Patients with CD seen in daily practice may differ 
frori1 the selected patients il1clnded in randomized trials 
(12-15]. In a mnlticenter open-label single-arm study 
(GARE), adalimumab the't:apy showed substanÜal effica- . 
' cy at week 4 (43% remission rate), which was sustained 
through week 20 (52% remissitm rate), including pàtients 
who had never responded to IFX [16]. Neither concomi-
tant steroids nor immunosuppréssants notably affécted 
the results [17]. In this study, we analyzed our experience 
· with adalimumab in · current clinical practice over the 
past 3 years. 
Patients and Methods 
We perforn1ed a retro'spective ch~rt review of patietlt.s with 
CD who had been tl'eated with adalimumab at tli'e University . 
Hospitals of Lansani1e, Geneva, Zurich and 01.ten between April 
2005 and April 2008, and 55 patients who had received adalim-
, umab were identified. The èliagnosis of CD was confirmed iri. all 
cases by a review of .patients' medical records including clinical 
notes, endoscopie, radiographie or hîstological documents. 
The information collected included patient demographics, 
disease location, disease phenotype, disease du ration, prior surgi-
.· cal procedures, smoking status, previous anti-TNF and immuno-
suppressant use, co11comitant médication, dis~ase activity at 
baseline and duringtreatment (table 1). Disease severity for lu mi-
na! CD was scored using the Harvey-Bradshaw index (HBI) [18]. 
For patients with pl'evious surgical resections, other causes of di-
arrhea, such as bile salt malabsorption, small bowel bacteriàl 
overgtowth, or deficient water absorption secondary to procto-
colecto1i1y, were eliminated before considering them for adalini.-
nmab therapy. 
The first clinical evaluation was performed at weeks 4-6. Sub~ 
seqnent assessments of the effîcacy of treatmênt were performed 
at weeks 12, 24 and 52. The clinical e'irolution ofluminal CD was 
classîfied into 3 i::ategories: remission, response, and non-re-
sponse: Remission was defined as an HBI of :54 and rcspohse as 
a reduction in the HBI of ;:::3 points at the evaluation: week com-
pared to thè baseline 'index [19]. The non~response càtegory in-
cluded all the. rcrnaining patients. ' 
Data on clinîcal safetywere collected at cvery medical vîsit and 
the patieflts were also înstruè:ted to contact the physician's office 
if any illness or adverse reaction occurred. Patients were consid-
ercd intolerant to IFX if they were unàble to ·continue the treat-
ment due to reactions judged by the clinician to be linked to the 
perfusion. Loss of responsiveness 1;o IFX was accepted if patients 
did not achieve reinission with an increased IFX regîmen after 
loss of efficacy at a standard dose. . 
We used univariate logistic regression analysis to sec if the 
predictive variables tested (table.2, 3) were implîcated in the re-
sponse rate. The variables which had a p value of<0.3 were tested,. 
then together i,11 a multivariate analysis in order to controlfor the 
confounding effect of each. A p value of <0.05 was cons'idered to . 
be statistically significant. Data are expressed accordingto.a.per-
prntocol analysis. All quantitative variabl.ès are expressed as the. 
mean ± standard error. 
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Table 1. Demographic and baselinè cliniçal characteristics (55 pa-
tients) 
Patient characteristics 
Gender 
Male 
Fe male 
Mean ·age, years 
Disease duration,. years 
Mean± SD 
Range 
Smokers 
Yes 
No 
Diseas.e location (Vienna classification) 
11: Ileal · 
12: Colonie 
13: Ileocolonic 
14: Upper (esophageal) 
Disease behavior 
11 
21 (38.2%) 
34 (61.8%) 
'37.5 
12.67 ± 11.4 
1-41 
29 (52.7%) 
26 (47.3%) 
9 (16.3%) 
11(20%)· 
35 (63.6%) 
1 (1.8%) 
{Vienna classification; patients may appear more than once) 
Bl: non-stricturing 11011-penetrating 35 (63'.6%) 
B2: stricturing 7 {12.7%) 
B3: penetrating 23 (41.8%) 
Surgery for Crohn' s di.sease 
Ileal resection 
Ileocolonic resection 
Colonie resection 
Proctocolectomy 
None 
Previous IFX therapy (n = 43) 
Side effects · · 
1oss of response 
No/insufficiént response 
Never given 
Type of IFX therapy 
Regular 
. ppisodic 
Coùcomitant trea.tm!"nt 
Budesonide 
Prednisone 
Azathioprine 
lyfethotrexate 
Indication of adalimumab · 
Intolerance to IFX 
Loss of response to IFX 
Corticodependence 
Other reason" 
Adalimumab induction regimen 
160/80 mg 
80/40 mg 
5 (9%) 
12 (21.8%) 
7'(12.7%) 
4 (7.3%) 
23 (41.8%) 
23/43 (53.4%) 
19/43 (44.2%) 
1/43 (2.3%) 
12/55 (21.9%) 
18/43 (41.9%) 
25/43 (58.1 %) 
4(7.3%) 
25 (45.4%) 
5 (9%) 
3 (5.4%) 
19 (34.5%) 
19 (34.5%) 
10 (18:1 %) 
7 (12.7%) 
31 (56.4%) 
24 (43.6%) 
. The value·s are the number of patients with percentages in pa-
rentheses. IFX = Infliximab. 
n Refractory to certolizumab (n = 3), to a·zathioprine (n = 1), 
extraintest\nal manifestations (n = 2), no respo'nse to IFX (n = 1). 
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· Results 
This cohort comprised 55 patients (21 men and 34 
women, iùean age 37.5 ± 11.4 years) treated with adali-
mumab behireen April 2005 and April 2008. The demo" 
graphie data and baseline clinical charactèristics are 
summarized in table 1. The mean duration of CD was 
12.7 (range 1-41) years. Description of disease loc«ltion 
ofluminal CD followed the usual distribution. One pa-
tient had ileal, col.onic and esophageal disease. The 
rnean HBI before treatmeht was 1.0.9 ± 5 points. Twen-
ty-nine patients weré smokers. Adalimumab was ad-
ministered to patients intolerant to IFX, to those who · 
had .lost response to IFX, or to those who were corti- · 
codependent. Seven patients were trèated thus for other 
reas.ons, 2 o'f whom had severe spondylarthropathy. The 
indication for adalîmumab therapy in the 4 patients 
who had an HBI of <4 points at inclusion was intolà-
ance to IFX (1 patient), lupus-like syndrome with IFX (1 
patient) and corticodependence (2 patients). These pa-
tients were considered to be ii1 reniission if their HBI 
remajned <4, or ·were deemed noi1-responders i'f their 
HBI value rose during the follow-up period. Of those 
who had already received IFX, 25 patients hàd episodic 
infusions and 18 patients had regular treatment. Ali pa-
tients received subcutaneous injections of adalimumab 
at weeks 0 aùd'2 at a dose of 160/80 mg (31 patients) or 
80/40 mg (24 patients) and then 40 mg every othei: week. 
Th~ resultsof detailed subgroup analysis are summa-
rized in tables 2 and 3. · 
Adalimwi1ab Induces and Maintains Clinical 
Remission and Response in CD Patients 
At weeks 21-6, in per-protocol analysis, remission had 
been induced. in 29 patients _(52.7%) and response was 
noted in 46 patients (83.6%). An adalimumab-inducecl re-
mission was maintained in 26 patients (89.6%) at wèek 12, 
and in 21 patients (72.4%) at week 24. The evolli,tion over 
time of remission and response rates in per-protocol 
analysis is shown in figure 1. However in a intentiùn-to-
. treat analysis remission was noticed in 47.3% patients at · 
week 24 and in 31% patients at week 52. Response rates at 
the same time points were 54.5 and 34.5%, respectively. 
· · Thirteen patients (23.6%) required an fo:crease in the 
adalimumab dose: 9 patierits t() 40. n1g every week, 2 pa-
tients to every 10 days, l patient to 80 mg every week, 
and another to 80 mg every 2 weeks, because of incoi11-
plete response or loss of response. Of these 13 patients, 6 
(46.1 %) achieved remission and another 2 patients re-
sponded. In 1 patient, the dose was reduced to 40 mg ev-
Nichita et al. 
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Table 2. Response by subgroups at 4-6 weeks 
Variable ·. Category Response . Nonresponse Univadate regression Multiva1:iate regression 
11(%) . n (%) 
OR(95% CI) p OR(95% CI) p 
Age, years 38.3 33.4 1.04 (0.97..:.1.12) 0.249 1.04 (0.97-1.12) 0.2158 
Gender Female 29 (85.3%) 5 (14.7%) 1 
Male 17 (80.9%) 4 (20.1%) . 0.73 (0.17-3.10) 0.673 
·Smoking status Non-smoker 23 (88.5%) 3 (11.4%) 1 
Smoker 23 (79.3%) 6 (20.7%) 0.50 (6.11-2.24) 0.366 
Disea.se duration, <7 15 (83%) .. 3 (17%) 1 
years <7-15 16 (84.%) 3 (17%) 1.00 (0.17-5.72) 1 
>15 15 (83%) 3 (17%) 0.94 (0.16-5.39) 0.942 
Disease location Ileitis (Ll) 8 (80%) 2 (20%) 1 
Colitis (L2) 10(91%) 1 (9%) 2.22 (0.17-8.86) 0.542 
Ileoçolitis (L3) 28 (82.3%)•. 6(17.3%) 1.04 (0.19-6.07) 0.968 
-----------
Previous resection No 18 (78.3%) 5 (21.,7%) 1 
(any segment) Yes 28 (87.5%) 4 (12.5%) 1.94 (0.46-8.22) 0.366 
Previous JFX Never . '9 (75%) 3 (25%) 1 
therapy Episodk 21 (84%) 4 (16%) 1.57 (0,29-SAI) 0.595 
Regular 16 (88.9%) 2 (10.1 %) 2.40 (0,34-6.97) 0.380 
Indication for Loss of response fo IFX i 7 (89.4%) 2 (10.6%) 1 1 
adalimumab Intolerance to IFX 17 (89.4%) . 2 (10.6%) 0:94(O.12-7.48) 0.957 1 
Other3 12 (70.5%) 5 (20.5%) 0.27 (0.04-1.61)' 0.149 0.33 (0.07-1.68) 0.182 
FirsHnonth total 12p (80+40) 19 5 (21%) 1 
dose, mg 240 (160+80) 27 4 (13%) 1.00 (ô.99-1.02) 0.434 
First-month total <2.5 17 (80.9%) A(19.1%) 1 1 
dose/weight, mg/kg 2.5-3.5 13 (76.4%) 4 (23.6%) o.n (0.15-:3.43) 0.682 1 
>3.5 16 (94..1%) l (5,9%) 3.56 (0.31,)-5.20) 0.278 3.87 (0.38-39.03) 0.251 
IFX = I;ifliximab. " Ccirticodepcndencé (n = 10) and oth~r (n = 7) merged because of srriall numbers. 
Table 3. Remission by subgroup's at 4-6 weeks 
Variable 
Smoker status· 
Previous IFX 
therapy 
Indication for i1dalimumàb 
IFX = Jnfliximab, 
Category 
Smoker 
Non-smokér 
Regulal' 
Episodic 
Nevâ 
Loss of respoilse to IFX 
Intolerance to IFX 
Re mission 
11 
12 (41.4%) 
17 (65.4%) 
10 (55.5%) 
12 (48%) 
7 (58.3%) 
8 (42.1%)· 
15 (78.9%) 
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Non-remission p value 
11 
17 (58.6%) 0.075 
9 (34.6%) 
8 (44.5%) 0.719 
13 (52%) 
5 (41.7%) 
n (57.9%) 0.012 
4 (21.1 %) 
81 
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Fig, 1, Response and remission· ràte ovçr time in per-protocol 
analysis. 
ery 4 weeks because of fatigue. The response rate was not 
significantly higher in the group of patients with ·previ-
ous abdominal sürgery (table 2). 
Effect of Smoking on Adalimumab Efficacy at 
Weeks4-6 · 
, The remissiori and response rates were higher among 
the non-smokers, but withouf any statiStically significant 
difference. 
Effect of Disease Duration or Location on 
Adalimumab Efficacy at Weeks 4-6 · 
Because of the long mean disease duration of oui· co-
hort, we chose to sep a rate the patients into 3 almost equal 
groups: CD known for <7 years, for 7-15 years and for 
>15 yeàrs. The remission and response rates were almost 
similar within these 3 groups. The location of the in tes-
. .tinal segment(s) involved was not found to. phiy a signifi-
cant role in patients' clinical response to the adalirirnmab 
therapy. 
Effect of the First-Month Total Dose 011 Adalimumab 
Efficacy àt Weeks 4-6 · 
Remission and response· tates were not different be- · 
tween the groups who received adalimumqb 2.40 or 120 
mg during the first mon th of treatment. The .total first~ 
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Table 4, Adverse events observèd over the 3-year period 
Type of adverse event n 
·None 30 
Perianal abscesses 2 
Asthenia 5 
Pi)in at injection site . 6 
Pruritis at injection site 2 
Rash· 1 
Headache 3 
Nausea 2 
Diarrhea 1 
Dizziness 2 
Phlebitis 1 
Gynecological sicle effect 1 
Labial herpes 1 
· Lupt1s-lilce syndn:ime_ 1 
month adalimumab dose was divided by the patient's 
weight and patients were then grouped into 3 dose-ad-
jüsted groups according to the total dose per kilogram 
over the first month: <2.5, 2.5-3.5 and >3.5 mg/kg. We 
did n_ot find any statistically significant difference be-
tween these 3' groups with regard to the response rate. 
Impact of Prior IFX Treatment 011 Adalimumab 
Efficacy at Weeks 4:..6 · 
The resporise rate was not influenced ,by the abs_ence 
·of previous IFX treatment t)r by its regular as opposed to 
episodie use. In contrast, the remission rate at weeks 4-6 
Was significantly hîgher among patients intolerarit to 
IFX, compai;ed to those who had lost response to this 
medication (78.9 vs. 42.1%, p = 0.02). 
Safety of Adal!mumab Treatme11t 
·Overall, subcutaneous injectiori$ of adalimumab 
were well tolerated (table 4). Thirty of the 55 patients 1 
repOrted no adverse event. The most common sicle effect 
was pain at the injection site (10.9%), follov\red by asthe-
nia (9%) and infections (7.2%). One patient stopped the 
treatment.because ofintolerable fatigue and another be-
cause of gynecological side effects, One case of lupus~ 
like .syndrome was noted. In our cohort, no fatal com-
plication, malignancy, neurologie. or ca1~diovascular 
complication was noted during the whole observàtion 
period. 
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Discussion 
The purpose of our retrospective cohort study was to 
eva!uate the effectiveness of adalinmmab in our Crohn's 
·patients over a period of 3 years in daily.clinical practice. 
Adalimum.ab treatment was effective in the induction and . 
n1aintenance of rei11ission in patients with moderatecto-
severe CD. The. results in our cohort appear better than the 
remission and response rates noticed in the CLASSIC I 
trial (36 and 59%, respectively, at week 4) [8] and the GAIN 
trial (21and52%, respectively, atweek 4) [11]. The fact that 
in our cohott the first .evaluation occurred later than in 
those trials, i.e. that our patients had a supplementary 
.third injection,,may have contril:\uted to the impi'oved re-
sults. In the per~protocol analysis,'44.7% patients were in 
remis si on and 50% still in resporl.se at week 52. Thesè long-
tenn results for remission are similar .to those at V\~eek 5'6 
in the CLASSIC II trial [9].' The limited size of our cohort, 
the lack of placebo controls and the absence of restricted 
inclusion criteria may have contributed to the difference.s 
noticed in our patients. In addition, we used the HBI rath-
er than the Crohn's Disease Activity Index to evaluate pa-
tients, which çould also in part exp Iain the difference from 
the randomized trial. The remission and response rates. in 
our cohort are also comparable to th ose of the CARE study 
[16, 17], although in this multicenter cohort all patients 
received a 160/80-mg inductionregimen. · 
The proportion of our patients who needed a dose in-
crease and the benefit obtained from this strategy ,{rere 
similar to those reported in the CHARM trial [20]. Ih our 
·cohort, ·the mean time· to. dose increase was relatively 
long: 7 (range 1-24) months. Our results thus confinn 
that in dinical practice this strategy shou1d be explored 
before considering another treatrüent in patients who 
lose response or fail to aéhieve complete remission with .a 
standard adalimumab regiinen. In a small study, a higher 
percentage of patients were previously reported to require 
an adalimumab dose increase (nearly 60% at 6 months) 
after using a suboptimal induction regimen of 80/40 n1g 
[12]. In another 2 cohorts, only 13.2 and 29% of patients 
requfred a dose increase [14, 15]. · 
In a per-protocol analysis, we ob_served that over 52 
weeks adalimumab treatment was stopped in half of the 
patients. This dropout rate was progressive during the 
observation period. The reasons for discontin_uation were · · 
either no response, loss of response despite dose increase 
(14/19 patients) or adverse reaction (5/19 patients). 
Smàking status had no effect on either the rate of clin-
ical 1;emission or the response rate in patients treated with 
adalimumab. This observation is consistent with the re-
Adalimumab in Crohn's Disease 
sults of the sub-analysis in the CLASSIC I triai, where the 
efficacy of adalimumab treatment at week 4 was not af-
fected by smoking status [21]. Hinojos<i et al. [13] also re-
ported no difference in. the 4~week response rate of active 
. smokei·s with luminal CD as compared to former smok-
ers. 
The effiéac;:y of adalimumab therapy in our cohort was · 
not influenced by disease duration. In the CHARM trial, 
Colom bel et al. [16] showed a significantly better remis-
sion rate at we.eks 26 and 56 with adalimumab in patiénts 
. with a CD duration of <2 or >5 years. We were unable to 
separate our patients into the saine 3 groups (disease du-
ration <2, 2-5 and >5 years) because our patients had a 
longstanding dfagnosis of CD. Our results suggest that a · 
diseàse dnration of >7 years has no grêater impact on re-
sponse .. 
We failed to show a correlation between tli.e total first 
month dose adapted to body weight or the respol'lse or 
remission ratè to adalimumab therapy. These results sug-
gest that the dose during the first month as currently ad-
ministered should suffice in the majority of patients. · 
However, the small size of the cohort and the retrospec-
. tive nature of the analysis do· not exclude the possibility 
. that a dose-weight · relationship rnight exist in a larger 
gronp of patients. Iùdeed, as .the affinities and molecular 
weight 'of IF:X and adalimumab are comparable, one 
could have expected that such a relationship might èxist. 
Other characteristics of adali1numab may explain this 
âifference as èompared to }FX, such as the human nature 
of the antibody or differences in the binding sites of the 
'antibodies. 
The majority of ourpatiertts had been treat.ed with IFX 
before receiving adalimumab. The remission and re-
sponse rates at weel<s 4-6 were not statistically different 
in patients naive to IFX compared to those who had al-. 
ready been trea'ted with IFX. Similarly, no difference was 
fonnd in the response to adalimumab betwèen patients 
whose previous IFX therapy was interrupted because of 
loss of response or because of intolerance. This last obser-
vation was also reported by Hinojosa et al. [13], In con-
trast, however, the remission rate at weeks 4-6 was sig-
nificantly higher in the subgroup of patients intolerant to 
IFX. This suggests that pàtients who did not lose their 
response to IFX may benefit more from another a11ti-TNF 
agent. Patients who have lost response may represent a . 
group of patients who fuay better benefit from a change 
in the ti'eatment target, different from TNF. 
Overall, adalimumab was well toierated in our cohort. 
The rate of sicle effects was similar to that already report-
eèi in randomized trials, in which patients underwe1;t 
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more stringent selection and monitoring [8-10). Pain at 
the injection site, asthenia a11d infections were the rnost 
cornrnon adverse ev'ents. Despite these reassuring results, 
the safety issues surronndiiig anti-TNF füerapies contin-
ue to be of greàt significance and clinicians need to re-
main vigÜant. Colomb el et al. (22] recently assessed glob-
al adalimumab safety in a collective of 2,228 patiènts ex-
posed to · adalimumab in pivota! randornized trials, 
open-label extensions and phase IIIb studies, CHOICE 
and GARE. The rates of opportunistic infections and ma-
lignant neoplasms were found to be <2% of patients. Su ch 
rates justify carefuf monitoring of all patients, even when 
stable in remission. 
Our study has several limitations. Firstly, the data pre-
sented are based on a retrospective review and ,not on a 
. uniform analysis with precise time points. Secondly, even 
if this is the largest cohort of open-label clinical. expéri-
ence in patients with CD to date, the number of patients 
analyzed at 24 and 52 weeks is still low. Thirdly, our pa-
tients had a long-standing CD history prior to adalim-
umab therapy. It remains to be studied if adalimumab 
used·in a top-down scheme rnight improve the.results re-
ported here. Although nonsignificant, the odds ratio val-
ues cannot be taken as proof that none of the variables 
mentioned in table 2 may have àri effect. The large confi-
dence intervals indicate that the calculatéd odds ratio re-
. mains imprecise. 
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